Matthew Kulke, MD, MMSc (Medical Oncology)Director, Program in Neuroendocrine and Carcinoid Tumors, Dana-Farber/Brigham and Women's Cancer Center Senior Physician Associate Professor of Medicine, Harvard Medical School & Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
44 Binney Street Dana 1220
Boston, MA 02115
Comments: We have established a robust clinical and translational research program at Dana-Farber Cancer Institute, focused on neuroendocrine tumors. As part of our clinical research program, we evaluate over 200 neuroendocrine tumor patients annually and have studied numerous novel therapies for neuroendocrine tumor patients.
SPECIAL NOTE: Dr. Kulke has been appointed Chief of Hematology/Oncology and Deputy Cancer Center Director at Boston University/Boston Medical Center, effective March 1, 2018. Dr. Kulke plans to maintain a clinical practice and research focus on neuroendocrine tumors in his new position. Information about contacting Dr. Kulke for appointments will follow soon.